Pharmacogenomics Market 2019-2025
- Id : RNR-199990
- Category : Pharma Healthcare
- Publish Date : May-2019
- Publisher : Research-N-Reports
- Pages : 123
- Format : PDF
Research N Reports added new report titled, “Pharmacogenomics (PGx) Market by Technology (Polymerase Chain Reaction (PCR), Microarray, Sequencing); by Ecosystem Players (Diagnostic Test, Pharmaceutical, Others); by Therapeutic Application (Oncology, Cardiovascular, Others); by Regions (North America, Asia Pacific, Europe, the Middle East & Africa and Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019-2025.” The Global Pharmacogenomics (PGx) Market growth is progressively gaining speed as a huge number of government initiatives and research & development programs have been introduced in the last few years. Development and invention of new healthcare technologies such as next-generation sequencing, High Throughput Screening (HTS), and Digital PCR are mounting the platform for growth. The Market, which was esteemed at US$ XX billion in 2017, is relied upon to achieve an estimation of US$ XX billion by 2025, developing at a CAGR of XX% amid the forecast time frame 2017-2025. The US market alone is forecast to be worth $XX billion in 2025, accounting for XX% of the overall Pharmacogenomics (PGx) market. On the basis of technology, the market is segmented into Polymerase Chain Reaction (PCR), microarray, sequencing and other technologies. Sequencing segment is further segmented into pyrosequencing, Sanger sequencing, and Next-Generation Sequencing (NGS). Other technologies are further segmented into mass spectrometry and electrophoresis. Observing current patterns, Big Data organizations are incorporating into service provider segments and are teaming up and entering into partnerships with healthcare suppliers, pharmaceuticals & biotechnology organizations, and academic institutions to help the development of the PGx market. As a consequence, the service segment is estimated to develop at a high CAGR of XX% from 2017 to 2025. Additionally, the Pharmaceutical segment will likewise gain from traction in number of patients because of expanding mindfulness about the advantages of PGx solutions and adoption of these solutions in developing regions. The market growth is propelled due to factors such as: • Rising usage in drug discovery processes. • Increasing demand for pharmacogenomics & precise drugs. • Technological innovation and advancement. • Increasing genetic disorder/abnormalities. • Government support and regulations. Government regulations and standards are supporting the development and advancement of the PGx market. The fundamental objective of these standards is to make the PGx solutions more versatile and centered toward oncology, pain management, the central nervous system (CNS), Cardiovascular (CVD), and infectious diseases among others. In North America, existing players are incorporating with new companies through partnerships and cooperation to capture the regional segment. The regions local players are entering in other emerging nations to capture more pieces of the overall industry. All through the Asia-Pacific and European nations, administrative bodies are rolling out standards to keep a check of most recent advancements. North America is the largest contributor to the revenue generation in PGx market followed by Europe and is expected to grow at a high CAGR of XX% from 2017 to 2025. APAC is expected to show the fastest growth globally and is expected to grow at XX% CAGR over the research period. The region is concentrating more on innovative development and presentation of new gene sequencing and gene mapping instruments into medicinal services frameworks to develop particular laboratory diagnostic tests. The report provides both, qualitative and quantitative research of the Global Pharmacogenomics (PGx) Market, as well as encompasses worthy insights into the rational scenario and favored improvement methods adopted by key contenders. Some of the primary players of Global Pharmacogenomics (PGx) Market are Abbott Laboratories, Affymetrix, Inc., Assurex Health, Inc., Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Pathway Genomics, Pfizer, Inc., Qiagen, Inc., Roche Holding Ag-Br, and Teva Pharmaceutical Industries Ltd., among others.